Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA): 7 pipeline candidates · 2 upcoming catalysts · ~20 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.4 months
D/E 0.42 · 28% dilution
Lead: Phase 3
7 candidates
2 upcoming, next in ~1809d
0 buys · 9 sells (180d)
A transparent, data-derived signal for Taysha Gene Therapies, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$276.6M
Quarterly Burn
$40.9M
Runway
20.4 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
191
Total value held
$1.09B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 23,555,648 | $105.3M |
| goldman sachs group inc | 22,369,645 | $100.0M |
| vanguard capital management llc | 20,463,004 | $91.5M |
| blackrock, inc. | 18,365,608 | $82.1M |
| morgan stanley | 17,965,371 | $80.3M |
| fmr llc | 14,321,255 | $64.0M |
| rtw investments, lp | 13,680,248 | $61.2M |
| state street corp | 11,209,078 | $50.1M |
| octagon capital advisors lp | 8,859,911 | $39.6M |
| siren, l.l.c. | 8,829,913 | $39.5M |
Showing top 10 of 191 institutional holders of Taysha Gene Therapies, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Taysha Gene Therapies, Inc.'s pipeline?
Taysha Gene Therapies, Inc. (TSHA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Taysha Gene Therapies, Inc.'s lead drug candidate?
Taysha Gene Therapies, Inc.'s most advanced tracked candidate is TSHA-102 (Phase 1) for Rett Syndrome.
What is Taysha Gene Therapies, Inc.'s next catalyst?
Taysha Gene Therapies, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dos" — expected June 1, 2031.
What is Taysha Gene Therapies, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Taysha Gene Therapies, Inc. has approximately 20.4 months of cash runway.
What is Taysha Gene Therapies, Inc.'s market capitalization?
Taysha Gene Therapies, Inc.'s market capitalization is approximately $1.8B.
Get the full picture on Taysha Gene Therapies, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.